Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial

被引：0
|
作者：
Celia A. J. Michielsens
Nadine Boers
Nathan den Broeder
Mark H. Wenink
Aatke van der Maas
Elien A. M. Mahler
Michelle L. M. Mulder
Désirée van der Heijde
Frank H. J. van den Hoogen
Lise M. Verhoef
Alfons A. den Broeder
机构：
[1] Sint Maartenskliniek,Department of Rheumatology
[2] Radboud Institute of Health Sciences,Department of Rheumatic Diseases
[3] Radboud University Medical Centre,Department of Rheumatology
[4] Leiden University Medical Centre,undefined
来源：
Trials | / 21卷
关键词：
Spondyloarthritis; Psoriatic arthritis; Dose reduction; Tapering; Randomised controlled trial; TNF inhibitors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial
    Michielsens, Celia A. J.
    Boers, Nadine
    den Broeder, Nathan
    Wenink, Mark H.
    van der Maas, Aatke
    Mahler, Elien A. M.
    Mulder, Michelle L. M.
    van der Heijde, Desiree
    van den Hoogen, Frank H. J.
    Verhoef, Lise M.
    ven Broeder, Alfons A.
    [J]. TRIALS, 2020, 21 (01)
  • [2] Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial
    Michielsens, Celia A. J.
    den Broeder, Nathan
    van den Hoogen, Frank H. J.
    Mahler, Elien A. M.
    Teerenstra, Steven
    van der Heijde, Desiree
    Verhoef, Lise M.
    den Broeder, Alfons A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (10) : 1392 - 1399
  • [3] TREAT-TO-TARGET DOSE REDUCTION AND WITHDRAWAL STRATEGY OF TNF INHIBITORS IN PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS: A RANDOMIZED CONTROLLED NON-INFERIORITY TRIAL
    Michielsens, C.
    den Broeder, N.
    van den Hoogen, F.
    Mahler, E.
    Teerenstra, S.
    van der Heijde, D.
    Verhoef, L. M.
    den Broeder, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 172 - 173
  • [4] Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis
    Jordi Gratacós
    Caridad Pontes
    Xavier Juanola
    Jesús Sanz
    Ferran Torres
    Cristina Avendaño
    Antoni Vallano
    Gonzalo Calvo
    Eugenio de Miguel
    Raimon Sanmartí
    [J]. Arthritis Research & Therapy, 21
  • [5] Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis
    Gratacos, Jordi
    Pontes, Caridad
    Juanola, Xavier
    Sanz, Jesus
    Torres, Ferran
    Avendano, Cristina
    Vallano, Antoni
    Calvo, Gonzalo
    de Miguel, Eugenio
    Sanmarti, Raimon
    Almirall, Miriam
    Aparicio, Maria
    Sellas, Agusti
    Vives, Roser
    Albinana, Nestor
    Moreno, Mireia
    Clavaguera, Teresa
    Carlos Torre-Alonso, Juan
    Veroz, Raul
    Rodriguez-Lozano, Carlos
    Francisco Linares, Luis
    Urruticoechea, Ana
    Collantes, Eduardo
    Maria Morla, Rosa
    Reina, Delia
    Cuende, Eduardo
    Zarco, Pedro
    Cruz Fernandez-Espartero, Maria
    Garcia-Vicuna, Rosario
    Alberto Montilla, Carlos
    Villalba, Alejandro
    Pascual, Dora
    Campos, Cristina
    Juan, Antonio
    Ariza, Rafael
    Diaz-Miguel, Consuelo
    Maqueda, Manuel
    Pilar Fernandez-Dapica, Maria
    Fernandez-Prada, Manuel
    Batlle, Enrique
    Gonzalez-Fernandez, Carlos
    Queiro, Ruben
    [J]. ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
  • [6] Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study
    Alfons A den Broeder
    Noortje van Herwaarden
    Aatke van der Maas
    Frank HJ van den Hoogen
    Johannes W Bijlsma
    Ronald F van Vollenhoven
    Bart JF van den Bemt
    [J]. BMC Musculoskeletal Disorders, 14
  • [7] Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study
    den Broeder, Alfons A.
    van Herwaarden, Noortje
    van der Maas, Aatke
    van den Hoogen, Frank H. J.
    Bijlsma, Johannes W.
    van Vollenhoven, Ronald F.
    van den Bemt, Bart J. F.
    [J]. BMC MUSCULOSKELETAL DISORDERS, 2013, 14
  • [8] A prediction model for successful increase of adalimumab dose intervals: analysis of the pragmatic open-label randomised controlled non-inferiority LADI trial
    Van Linschoten, R.
    Jansen, F.
    Pauwels, R.
    Smits, L.
    Atsma, F.
    Kievit, W.
    de Jong, D.
    de Vries, A.
    Boekema, P.
    West, R.
    Bodelier, A.
    Gisbertz, I.
    Wolfhagen, F.
    Romkens, T.
    Lutgens, M.
    van Bodegraven, A.
    Oldenburg, B.
    Pierik, M.
    Russel, M.
    de Boer, N.
    Mallant-Hent, R.
    ter Borg, P.
    van der Meulen-de Jong, A.
    Jansen, J.
    Jansen, S.
    Tan, A.
    van der Woude, C. J.
    Hoentjen, F.
    [J]. JOURNAL OF CROHNS & COLITIS, 2023, 17 : 655 - 658
  • [9] Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial
    van Herwaarden, Noortje
    van der Maas, Aatke
    Minten, Michiel J. M.
    van den Hoogen, Frank H. J.
    Kievit, Wietske
    van Vollenhoven, Ronald F.
    Bijlsma, Johannes W. J.
    van den Bemt, Bart J. F.
    den Broeder, Alfons A.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2015, 350
  • [10] Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial
    l'Ami, Merel J.
    Krieckaert, Charlotte L. M.
    Nurmohamed, Michael T.
    van Vollenhoven, Ronald F.
    Rispens, Theo
    Boers, Maarten
    Wolbink, Gerrit Jan
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (04) : 484 - 487
12345